Risk of malignancy in patients treated for systemic necrotising vasculitis.

• Lafarge A Department of Internal Medicine, Cochin Hospital, Paris, France antoinelafarge@outlook.com benjamin.terrier@aphp.fr.
• Joseph A U1138, INSERM, Paris, France.
• Pagnoux C Department of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada.
• Puechal X Department of Internal Medicine, Cochin Hospital, Paris, France.
• Cohen P Department of Internal Medicine, Cochin Hospital, Paris, France.
• Samson M Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, Dijon, France.
• Hamidou M Department of Internal Medicine, Hôtel Dieu, Nantes, France.
• Karras A Department of Nephrology, Hôpital Européen Georges Pompidou, Paris, France.
• Groh M Department of Internal Medicine, Cochin Hospital, Paris, France.
• Quemeneur T Department of Internal Medicine, Hôpital de Valenciennes, Valenciennes, France.
• Ribi C Department of Immunology, CHUV, Lausanne, Switzerland.
• Mouthon L Department of Internal Medicine, Cochin Hospital, Paris, France.
• Guillevin L Department of Internal Medicine, Cochin Hospital, Paris, France.
• Terrier B Department of Internal Medicine, Cochin Hospital, Paris, France antoinelafarge@outlook.com benjamin.terrier@aphp.fr.

Show more…

cancer

cyclophoshamide

immunosuppressive agents

rituximab

vasculitis

Aged

Cyclophosphamide

Female

Humans

Immunosuppressive Agents

Male

Middle Aged

Necrosis

Neoplasms

Randomized Controlled Trials as Topic

Risk Factors

Treatment Outcome

Vasculitis